Compile Data Set for Download or QSAR
maximum 50k data
Found 132 Enz. Inhib. hit(s) with all data for assayid = 1 entry = 1564
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615197(US20230271945, Compound 117)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615198(US20230271945, Compound 118)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615200(US20230271945, Compound 120)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM50547880(CHEMBL4789274 | US20230271945, Compound 121)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615202(US20230271945, Compound 122)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615203(US20230271945, Compound 123)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615204(US20230271945, Compound 124)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615205(US20230271945, Compound 125)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615206(US20230271945, Compound 126)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615208(3-[2-(4-chlorophenyl)-1H-indol-3-yl]-N-[(3S,4R)-4-...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615209(3-[2-(3,4-difluorophenyl)-1H-indol-3-yl]-N-[(3S,4R...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615210(2-[[2-(4-fluorophenyl)-1H-indol-3-yl]sulfanyl]-N-[...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615124(3-[2-(4-bromophenyl)-5-methyl-1H-indol-3-yl]-N-[(3...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615125(3-(5-chloro-2-phenyl-1H-indol-3-yl)-N-[(3S,4R)-4-h...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615126(3-[5-chloro-2-(4-fluorophenyl)-1H-indol-3-yl]-N-[(...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615127(US20230271945, Compound 46)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615128(US20230271945, Compound 47)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615129(US20230271945, Compound 48)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615132(US20230271945, Compound 51)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615133(US20230271945, Compound 52)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615139(US20230271945, Compound 58)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615140(US20230271945, Compound 59)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM50547878(CHEMBL4752052 | US20230271945, Compound 61)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615143(N-[(3S,4R)-4-hydroxy-2-oxo-pyrrolidin-3-yl]-3-(2-p...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615144(US20230271945, Compound 63)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615150(US20230271945, Compound 69)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615151(US20230271945, Compound 70)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615152(US20230271945, Compound 71)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615153(US20230271945, Compound 72)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615154(US20230271945, Compound 73)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615155(US20230271945, Compound 74)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615156(US20230271945, Compound 75)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615157(US20230271945, Compound 76)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615160(US20230271945, Compound 79)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615161(US20230271945, Compound 80)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615162(US20230271945, Compound 81)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM50547879(CHEMBL4780017 | US20230271945, Compound 82)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615164(US20230271945, Compound 83)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615165(US20230271945, Compound 84)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615166(US20230271945, Compound 85)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615167(US20230271945, Compound 86)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615211(3-[2-[4-(difluoromethyl)phenyl]-1H-indol-3-yl]-N-[...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615212(3-[5-fluoro-2-phenyl-7-(trifluoromethyl)-1H-indol-...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM50547875(CHEMBL4754532 | US20230271945, Compound 1)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615085(3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]-...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615086(3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]-...)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM50547876(CHEMBL4791770 | US20230271945, Compound 20)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615102(US20230271945, Compound 21)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615103(US20230271945, Compound 22)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApolipoprotein L1(Homo sapiens)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615104(US20230271945, Compound 23)
Affinity DataIC50:  600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 132 total ) | Next | Last >>
Jump to: